• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    OPKO Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    4/23/25 4:09:15 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPK alert in real time by email
    opk20250417c_8k.htm
    false 0000944809 0000944809 2025-04-23 2025-04-23
     


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): April 23, 2025
     
    OPKO Health, Inc.
    (Exact Name of Registrant as Specified in its Charter)
     
    Delaware
     
    001-33528
     
    75-2402409
    (State or Other Jurisdiction
    of Incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)
     
    4400 Biscayne Blvd.
    Miami,
    Florida
     
    33137
    (Address of Principal Executive Offices)
     
    (Zip Code)
    Registrant’s telephone number, including area code: (305) 575-4100
     
    Not Applicable
    Former name or former address, if changed since last report
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.01 per share
    OPK
    NASDAQ Global Select Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company         ☐         
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                  ☐
     


     
     

     
     
    ITEM 5.07.
    Submission of Matters to a Vote of Security Holders.
     
    On April 23, 2025, the Company held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”).  Below is a summary of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting and the corresponding votes.
     
    1. All eleven nominees were elected to the Board of Directors with each director receiving votes as follows:
     
    Election of Directors
     
    For
     
    Against
     
    Abstain
     
    Broker Non-Votes
    Phillip Frost, M.D.
     
    434,964,129
     
    15,405,532
     
    398,538
     
    76,193,825
    Jane H. Hsiao, Ph.D.
     
    437,774,692
     
    12,596,864
     
    396,643
     
    76,193,825
    Elias A. Zerhouni, M.D.
     
    434,808,543
      15,565,748  
    393,908
     
    76,193,825
    Steven D. Rubin
     
    431,540,459
     
    18,851,054
     
    376,686
     
    76,193,825
    Gary J. Nabel, M.D., Ph.D.
     
    433,141,213
      17,199,627  
    427,359
     
    76,193,825
    Richard M. Krasno, Ph.D.
     
    442,890,267
     
    7,401,828
     
    476,104
     
    76,193,825
    Prem A. Lachman, M.D.
     
    444,341,039
     
    5,584,697
     
    842,463
     
    76,193,825
    Roger J. Medel, M.D.
     
    444,507,113
     
    5,408,979
     
    852,107
     
    76,193,825
    John A. Paganelli
     
    428,765,752
     
    21,193,856
     
    808,591
     
    76,193,825
    Richard C. Pfenniger, Jr.
     
    444,585,339
     
    5,672,331
     
    510,529
     
    76,193,825
    Alice Lin-Tsing Yu, M.D., Ph.D.
     
    444,805,156
      5,495,434  
    467,609
     
    76,193,825
     
     
    2. The stockholders voted to approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Company’s 2025 Proxy Statement for the Annual Meeting. The votes on this proposal were as follows:
     
    For
     
    Against
     
    Abstain
     
    Broker Non-Votes
     
     
     
     
     
     
     
    439,260,125
     
    10,995,027
     
    513,047
     
    76,193,825
     
     
    3. The stockholders voted to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The votes on this proposal were as follows:
     
    For
     
    Against
     
    Abstain
     
    Broker Non-Votes
     
     
     
     
     
     
     
    522,666,577
     
    3,921,683
     
    373,764
     
    0
     
    No other matters were considered or voted upon at the meeting.
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
       
    OPKO Health, Inc.
           
       
    By:
    /s/ Steven D. Rubin
    Date: April 23, 2025
     
    Name:
    Steven D. Rubin
       
    Title:
    Executive Vice President - Administration
           
     
     
    Get the next $OPK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPK

    DatePrice TargetRatingAnalyst
    4/25/2025Neutral
    Analyst
    6/29/2023$2.00Mkt Perform → Outperform
    Barrington Research
    12/15/2022$3.00Buy
    H.C. Wainwright
    1/24/2022Outperform → Market Perform
    Barrington Research
    More analyst ratings

    $OPK
    SEC Filings

    See more
    • OPKO Health Inc. filed SEC Form 8-K: Leadership Update

      8-K - OPKO HEALTH, INC. (0000944809) (Filer)

      5/29/25 5:00:31 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by OPKO Health Inc.

      10-Q - OPKO HEALTH, INC. (0000944809) (Filer)

      5/1/25 4:04:56 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OPKO HEALTH, INC. (0000944809) (Filer)

      4/30/25 4:07:22 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $OPK
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $OPK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Analyst initiated coverage on Opko Health

      Analyst initiated coverage of Opko Health with a rating of Neutral

      4/25/25 8:32:28 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opko Health upgraded by Barrington Research with a new price target

      Barrington Research upgraded Opko Health from Mkt Perform to Outperform and set a new price target of $2.00

      6/29/23 9:11:26 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Opko Health with a new price target

      H.C. Wainwright initiated coverage of Opko Health with a rating of Buy and set a new price target of $3.00

      12/15/22 8:08:28 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health to Participate in Two Upcoming Investor Conferences

      MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today that management will be participating in two investor conferences over the coming weeks. H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will hold one-on-one meetings with investors and will participate in a fireside discussion at 9:00 a.m. Eastern time. Jefferies Global Healthcare Conference, June 3-5 at the Marriott Marquis in New York City. Management will hold one-on-one meetings with investors on Wednesday, June 4th and will participate in a fireside discussion on Wednesday, June 4th at 11:05 a.m. Eastern time. The fireside discussions

      5/15/25 8:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results

      MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReference). The transaction includes the sale of BioReference's laboratory testing businesses focused on oncology and oncology-related clinical testing services for up to $225 million, including $192.5 million payable at closing and up to $32.5 million in an earnout based on performance. BioReference will continue to

      4/30/25 4:05:00 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025

      MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Wednesday, April 30, 2025. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 30th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participan

      4/17/25 8:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & Chairman Frost Phillip Md Et Al bought $169,712 worth of shares (125,000 units at $1.36) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/10/25 5:07:15 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & Chairman Frost Phillip Md Et Al bought $184,650 worth of shares (125,000 units at $1.48) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/8/25 5:34:21 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & Chairman Frost Phillip Md Et Al bought $164,850 worth of shares (100,000 units at $1.65) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/1/25 5:21:45 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPK
    Leadership Updates

    Live Leadership Updates

    See more
    • OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

      WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera

      9/23/24 8:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jon Cohen and Michael Hansen Join Talkspace's Board of Directors

      NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (NASDAQ:TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company's board of directors and approved all other shareholder proposals during the company's first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Health (NASDAQ:OPK). Dr. Cohen brings 30 years of healthcare industry strategy and operating experience to Talkspace's board of directors. He succeeds Jeffrey Crowe as an independent Class I Director with a term expiring in 2025. Additionally, the Company's board appointed C

      9/15/22 4:05:00 PM ET
      $OPK
      $TALK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Nursing Services
    • OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx

      MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO's BioReference Laboratories. Ms. Stueland joins GeneDx from Invitae Corporation (NYSE:NVTA), where she served most recently as Chief Commercial Officer, establishing the corporate brand as Invitae evolved from a private company to a public entity with a market capitalization exceeding $6 billion.  "We're thrilled to have Katherine lead the team at GeneDx, which has served clinicians and patients for more than two decades with novel and differentiated technologies for di

      6/22/21 8:00:00 AM ET
      $OPK
      $NVTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities

    $OPK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

      SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

      11/15/24 4:39:33 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by OPKO Health Inc.

      SC 13G - OPKO HEALTH, INC. (0000944809) (Subject)

      11/13/24 4:30:24 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OPKO Health Inc.

      SC 13G/A - OPKO HEALTH, INC. (0000944809) (Subject)

      11/12/24 4:54:06 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO & Chairman Frost Phillip Md Et Al

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      5/29/25 5:08:32 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vice Chairman & CTO Hsiao Jane Ph D

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      5/29/25 5:07:08 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vice Chairman and President Zerhouni Elias A.

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      5/29/25 5:05:24 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPK
    Financials

    Live finance-specific insights

    See more
    • OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results

      MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReference). The transaction includes the sale of BioReference's laboratory testing businesses focused on oncology and oncology-related clinical testing services for up to $225 million, including $192.5 million payable at closing and up to $32.5 million in an earnout based on performance. BioReference will continue to

      4/30/25 4:05:00 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025

      MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Wednesday, April 30, 2025. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 30th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participan

      4/17/25 8:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

      MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial. Dosing of patients has commenced for the Phase I study (NCT06655324) of an EBV vaccine candidate being developed in collaboration with Merck. The investigational vaccine, based on ModeX's ferritin nanoparticle vaccine platform, is being evaluated for safety and tolerability in up to 200 healthy adults. Commencement of this study triggere

      2/27/25 4:10:15 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care